Go to ScienceDirect® Home Skip Main Navigation Links
 Register or Login:   Password:     Athens Login 
HomeBrowse JournalsBrowse Abstract DatabasesBrowse BooksBrowse Reference WorksMy ProfileAlerts Help (Opens new window)
The Lancet
Volume 355, Issue 9200 , 22 January 2000, Pages 289-290

This Document
Abstract
Full Text + Links
PDF (324 K)
Actions
E-mail Article

doi:10.1016/S0140-6736(99)03514-X    How to cite or link using doi (opens new window) Cite or link using doi  
Copyright © 2000 Elsevier Science Ltd. All rights reserved.

Research Letters

Neuroleptic malignant syndrome after venlafaxine

Seshagiri Rao Nimmagadda MBBSCorresponding Author Contact Information, E-mail The Corresponding Author, a, David Hugh Ryan MRCPsychb and Stephen Lawrence Atkin FRCPc

a Acute Psychiatric Assessment Unit, Millview Court, Castle Hill Hospital, Cottingham, Hull, UK
b Community Mental Health Unit, Beverly, East Yorkshire, UK
c Hull Royal Infirmary, Anlaby Road, Hull, UK

Available online 18 February 2000.


Abstract

A patient developed neuroleptic malignant syndrome after a single dose of venlafaxine with trifluoperazine treatment. A dopamine-inhibition effect induced by one dose of venlafaxine may have augmented dopamine-receptor inhibition by trifluoperazine.


Corresponding Author Contact Information Corresponding author; email: seshagiri25@hotmail.com



This Document
Abstract
Full Text + Links
PDF (324 K)
Actions
E-mail Article
The Lancet
Volume 355, Issue 9200 , 22 January 2000, Pages 289-290


 
HomeBrowse JournalsBrowse Abstract DatabasesBrowse BooksBrowse Reference WorksMy ProfileAlerts Help (Opens new window)

Send feedback to ScienceDirect
Software and compilation © 2004 ScienceDirect. All rights reserved.
ScienceDirect® is a registered trademark of Elsevier B.V.


Your use of this service is governed by Terms and Conditions. Please review our Privacy Policy for details on how we protect information that you supply.